Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last kr2.00 SEK
Change Today 0.00 / 0.00%
Volume 10.1K
As of 5:48 AM 08/5/15 All times are local (Market data is delayed by at least 15 minutes).

genovis ab (GENO) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/1/14 - kr3.30
52 Week Low
12/9/14 - kr1.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GENOVIS AB (GENO)

Related News

No related news articles were found.

genovis ab (GENO) Related Businessweek News

No Related Businessweek News Found

genovis ab (GENO) Details

Genovis AB (publ) develops and sells enzymes in various product formats that facilitate development and quality control of biological drugs. The company’s products comprise FabRICATOR, an enzyme with proteolytic activity in hinge regions of IgG; FragIT, a FabRICATOR enzyme immobilized on agarose allowing for antibody subunit fragmentation without contaminating the final preparation with FabRICATOR enzyme; and FragIT kit that creates and isolates F(ab')2 and Fc fragments from IgG. It also offers FabULOUS, an enzyme that digests antibodies from various species and subclasses in the upper hinge region; and GlycINATOR, an endoglycosidase for minimizing side effects in various immunoassays caused by complement binding or cross-reactivity. In addition, the company provides IgGZERO, a recombinantely modified Endoglycosidase S from streptococcus pyogenes; and DeGlycIT, which is an IgGZERO (EndoS) enzyme that allows for removal of N-linked glycans associated to the Fc domain of IgG. Further, it develops a series of nanostructures for use as contrast agents in medical imaging. Genovis AB (publ) serves biotech and pharmaceutical companies, contract research companies, and contract manufacturing companies. The company operates in Nordic Countries, Germany, the Netherlands, France, Rest of Europe, North America, and other countries. Genovis AB (publ) was founded in 1999 and is based in Lund, Sweden.

16 Employees
Last Reported Date: 04/15/15
Founded in 1999

genovis ab (GENO) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

genovis ab (GENO) Key Developments

Genovis Announces Management Changes

Sarah Fredriksson, founder of Genovis, will hand over the reins at the AGM on May 5 to Fredrik Olsson, who will become the new CEO of the company. The Nomination Committee has submitted a new proposal to the AGM and proposes that Sarah Fredriksson be elected to serve as the new Chair of the Board. Sarah Fredriksson will remain in the company with responsibility for the subsidiary GeccoDots.

Genovis AB Reports Consolidated and Company Earnings Results for the First Quarter Ended March 31, 2015

Genovis AB reported consolidated and company earnings results for the first quarter ended March 31, 2015. For the period, on consolidated basis, the company’s net sales were SEK 2,886,000 against SEK 1,984,000 a year ago. Operating loss before depreciation, amortization and impairment was SEK 4,667,000 against SEK 3,604,000 a year ago. Operating loss was SEK 5,000,000 against SEK 3,878,000 a year ago. Loss attributable to shareholders in company was SEK 5,006,000 against SEK 3,838,000 a year ago. Basic and diluted loss per share was SEK 0.23 against SEK 0.19 a year ago. Cash used in operating activities was SEK 4,854,000 against SEK 6,213,000 a year ago. Consolidated capital expenditure during the period totaled SEK 610,000 of which SEK 10,000 is attributable to property, plant, and equipment, primarily laboratory equipment and computers, and SEK 600,000 is attributable to investments in intangible fixed assets. For the period, the company’s operating income was SEK 3,377,000 against SEK 2,751,000 a year ago. Operating loss was SEK 3,975,000 against SEK 2,924,000 a year ago. Loss before tax was SEK 5,028,000 against SEK 3,834,000 a year ago. Loss for the period was SEK 5,028,000 against SEK 3,834,000 a year ago. Cash used in operating activities was SEK 3,056,000 against SEK 4,820,000 a year ago.

Genovis Proposes Amendment to its Articles of Association

Genovis proposed the amendment to its articles of association, at its annual general meeting to be held on May 5, 2015. The company's articles of association, item 4, shall be amended as follows: Share capital shall amount to a minimum of SEK 5,250,000 and a maximum of SEK 21,000,000 instead of the current SEK 2,400,000 and maximum of SEK 9,600,000. The company's articles of association, item 5, shall be amended as follows: The number of shares that the company may issue shall be a minimum of 21,000,000 and a maximum of 84,000,000, instead of the current minimum of 6,000,000 and a maximum of 24,000,000.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GENO:SS kr2.00 SEK 0.00

GENO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $148.97 USD -0.67
View Industry Companies

Industry Analysis


Industry Average

Valuation GENO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.2x
Price/Book 4.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENOVIS AB, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at